Intravascular Injections of Adenoassociated Viral Vector Serotypes rh10 and PHP.B Transduce Murine Sciatic Nerve Axons

share:

Brief intro:

Products/Services used in the paper

Quotation shows PackGene:AAVPHP.B (CMV.EGFP.WPRE.SV40pA) was obtained from Packgene (Worcester, MA).

Research Field:CNS

AAV Serotype:AAVPHP.B

Targeted organ:Peripheral Nerve Axons

Animal or cell line strain:Eleven-week-old, female C57BL/6J mice (Jackson Laboratory; Bar Harbor, ME)

Request Quote

Abstract

Adenoassociated viral vectors provide a safe and robust method for expression of transgenes in nondividing cells such as neurons. Intravenous injections of these vectors provide a means of transducing motoneurons of peripheral nerves. Previous research has demonstrated that serotypes 1, rh10 and PHP.B can transduce motor neuron cell bodies in the spinal cord, but has not quantified expression in the peripheral nerve axon. Axonal labeling is crucial for optogenetic stimulation and detection of action potentials in peripheral nerve. Therefore, in this study, serotypes 1, PHP.B, and rh10 were tested for their ability to label axons of the murine sciatic and tibial nerve following intravenous injection. Serotype rh10 elicits expression in 10% of acetylcholine transferase positive axons of the sciatic nerve in immuno histochemically-stained sections. Serotype rh10 transduces a variety of axon diameters from <1–12 microns, while PHP.B transduces larger axons of diameter (4–16 microns). Expression was not seen with serotype 1. These results show the potential of serotypes PHP.B and rh10 delivery of transgenic products to axons of the peripheral nerve.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download